ZS Oncology Value Watchdog Report: 340B Drug Pricing Program | ZS

Insights

ZS Oncology Value Watchdog Report: 340B Drug Pricing Program

Christina Corridon

 


> Download

The 340B Drug Discount Program is a federal plan to encourage hospitals with disproportionate shares of uninsured patients to continue providing services to the patients by reducing the financial burden. The program has rapidly grown over the last several years due to continued expansion of practice eligibility. The Health Resources and Services Administration and drug manufacturers are collaborating to bring the reforms to the 340B Program. This Value Watchdog Report summarizes facts related to the 340B program and implications for pharmaceutical companies.                 


About the Expert





Christina Corridon is a Manager in the Boston office and a leader in the ZS Oncology Practice. She has over a decade experience working in the pharmaceutical and biotech industries, with specific expertise in oncology and biosimilars. During her consulting career she has worked on US and global projects spanning commercialization strategy including launch strategy and planning, go-to market strategy, commercial models, marketing strategy and brand planning. Christina has an MPH in Health Policy and Management from the UCLA Fielding School of Public Health and an MBA from the Stern School of Business at New York University focused in Marketing. Christina completed her BA at Cornell University.

Contact ZS